Techno Trends
Techno Trends includes advancements and innovations in pharmaceutical products and technology from around the world. Additionally, you may keep abreast of any recent advancements in the pharmaceutical industry (product information and technological trends).
FDA Authorises Aletta for Autonomous Blood Collection
The U.S. Food and Drug Administration (FDA) has authorised Aletta, the first standalone robotic device designed to collect blood from a patient’s arm without hands-on operator intervention....
DeepCyte Launches AI-Powered Atlas for Drug Toxicity Prediction
DeepCyte Inc. has launched DeeTox Atlas™, a single-cell metabolomics reference atlas designed to advance AI-based prediction of drug toxicity mechanisms....
Rein Therapeutics Gains FDA Fast Track for LTI-03 in IPF
Rein Therapeutics has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for LTI-03, an investigational therapy being developed to treat idiopathic pulmonary fibrosis (IPF)....
Bristol Myers Squibb Secures FDA Approval for ZENBEXUS in Multiple Myeloma
Bristol Myers Squibb (BMS) has received US Food and Drug Administration (FDA) approval for ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd)....
Galibra Gains FDA Designations for SSADH Gene Therapy
Galibra Neuroscience has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration (FDA) for its investigational gene therapy for succinic semialdehyde dehydrogenase (SSADH) deficiency....
Dianthus Advances DNTH312 Dual-Target Approach for Severe Autoimmune Diseases
Dianthus Therapeutics has announced DNTH312, an investigational bifunctional fusion protein being developed to treat severe autoimmune diseases....
GSK Wins FDA Approval for Jideytro in ROS1-Positive NSCLC
GSK has received US Food and Drug Administration (FDA) approval for Jideytro (zidesamtinib), a selective ROS1 inhibitor for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer...
Otsuka’s SIMTRIYO Receives FDA Approval for ADHD Treatment
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. have announced that the U.S. FDA has approved...
University Researchers Develop CAR T Therapy Candidate for Solid Tumour Treatment
Researchers from the University of Calgary and McMaster University have developed a novel CAR T cell therapy approach targeting treatment-resistant solid tumours....
Vera Therapeutics Secures FDA Accelerated Approval for TRUTAKNA to Treat Primary IgA Nephropathy
Vera Therapeutics has received accelerated approval from the US Food and Drug Administration (FDA) for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression....
